Stifel raised the firm’s price target on MBX Biosciences (MBX) to $56 from $50 and keeps a Buy rating on the shares following the company’s investor day meeting.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- MBX Biosciences price target raised to $70 from $66 at Barclays
- MBX Biosciences price target raised to $86 from $76 at Citizens
- MBX Biosciences price target raised to $70 from $50 at Truist
- MBX Biosciences Phase 1 data supports once-monthly dosing for MBX 4291
- MBX Biosciences Highlights Positive Phase 1 Obesity Data